Tomofumi Osako - Search Results

Year	Number of Results
2006	2
2010	2
2011	4
2012	4
2013	3
2014	1
2015	6
2016	6
2017	3
2018	2
2019	3
2020	2
2021	1
2022	2
2023	3
2024	1

1

Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole.

Takahashi M, Osako T, Yasojima H, Inoue K, Kawashima M, Maeda H, Ichikawa A, Muramatsu Y, Masuda N. Takahashi M, et al. Among authors: osako t. Breast Cancer. 2024 Jan;31(1):53-62. doi: 10.1007/s12282-023-01511-z. Epub 2023 Oct 26. Breast Cancer. 2024. PMID: 37882974 Free PMC article.

2

Efficacy and safety of pegfilgrastim biosimilar MD-110 in patients with breast cancer receiving chemotherapy: Single-arm phase III.

Takano T, Ito M, Kadoya T, Osako T, Aruga T, Masuda N, Miyaki T, Niikura N, Shimizu D, Yokoyama Y, Watanabe M, Tomomitsu M, Aogi K. Takano T, et al. Among authors: osako t. Cancer Med. 2023 Oct;12(20):20242-20250. doi: 10.1002/cam4.6519. Epub 2023 Oct 12. Cancer Med. 2023. PMID: 37824431 Free PMC article. Clinical Trial.

3

Microsatellite instability in Japanese female patients with triple-negative breast cancer.

Kurata K, Kubo M, Kai M, Mori H, Kawaji H, Kaneshiro K, Yamada M, Nishimura R, Osako T, Arima N, Okido M, Oda Y, Nakamura M. Kurata K, et al. Among authors: osako t. Breast Cancer. 2020 May;27(3):490-498. doi: 10.1007/s12282-019-01043-5. Epub 2020 Jan 6. Breast Cancer. 2020. PMID: 31907878 Free PMC article.

4

Granzyme B Expression in the Tumor Microenvironment as a Prognostic Biomarker for Patients with Triple-Negative Breast Cancer.

Mizoguchi K, Kawaji H, Kai M, Morisaki T, Hayashi S, Takao Y, Yamada M, Shimazaki A, Osako T, Arima N, Okido M, Oda Y, Nakamura M, Kubo M. Mizoguchi K, et al. Among authors: osako t. Cancers (Basel). 2023 Sep 7;15(18):4456. doi: 10.3390/cancers15184456. Cancers (Basel). 2023. PMID: 37760424 Free PMC article.

5

An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer.

Nishimura R, Osako T, Okumura Y, Nakano M, Ohtsuka H, Fujisue M, Arima N. Nishimura R, et al. Among authors: osako t. Oncol Lett. 2022 Jun 7;24(2):245. doi: 10.3892/ol.2022.13366. eCollection 2022 Aug. Oncol Lett. 2022. PMID: 35761943 Free PMC article.

6

Clinical Significance of CK19 Negative Breast Cancer.

Fujisue M, Nishimura R, Okumura Y, Tashima R, Nishiyama Y, Osako T, Toyozumi Y, Arima N. Fujisue M, et al. Among authors: osako t. Cancers (Basel). 2012 Dec 21;5(1):1-11. doi: 10.3390/cancers5010001. Cancers (Basel). 2012. PMID: 24216695 Free PMC article.

7

Triple Negative Breast Cancer: An Analysis of the Subtypes and the Effects of Menopausal Status on Invasive Breast Cancer.

Nishimura R, Osako T, Okumura Y, Nakano M, Otsuka H, Fujisue M, Arima N. Nishimura R, et al. Among authors: osako t. J Clin Med. 2022 Apr 22;11(9):2331. doi: 10.3390/jcm11092331. J Clin Med. 2022. PMID: 35566456 Free PMC article.

8

T-bet⁺ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer.

Mori H, Kubo M, Kai M, Yamada M, Kurata K, Kawaji H, Kaneshiro K, Osako T, Nishimura R, Arima N, Okido M, Kishimoto J, Oda Y, Nakamura M. Mori H, et al. Among authors: osako t. Breast Cancer Res Treat. 2019 Aug;176(3):569-577. doi: 10.1007/s10549-019-05256-2. Epub 2019 May 8. Breast Cancer Res Treat. 2019. PMID: 31069590 Free PMC article.

9

The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.

Takahashi M, Ohtani S, Nagai SE, Takashima S, Yamaguchi M, Tsuneizumi M, Komoike Y, Osako T, Ito Y, Ikeda M, Ishida K, Nakayama T, Takashima T, Asakawa T, Matsumoto S, Shimizu D, Masuda N. Takahashi M, et al. Among authors: osako t. Breast Cancer Res Treat. 2021 Jan;185(1):125-134. doi: 10.1007/s10549-020-05921-x. Epub 2020 Sep 13. Breast Cancer Res Treat. 2021. PMID: 32920732 Free PMC article. Clinical Trial.

10

Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.

Yamashita H, Ogiya A, Shien T, Horimoto Y, Masuda N, Inao T, Osako T, Takahashi M, Endo Y, Hosoda M, Ishida N, Horii R, Yamazaki K, Miyoshi Y, Yasojima H, Tomioka N; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Yamashita H, et al. Among authors: osako t. Breast Cancer. 2016 Nov;23(6):830-843. doi: 10.1007/s12282-015-0649-0. Epub 2015 Oct 14. Breast Cancer. 2016. PMID: 26467036 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

35 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year